Optibrium and Collaborative Drug Discovery partner on integration of StarDrop with CDD Vault
Collaboration provides a comprehensive platform for data management, analysis and compound design in drug discovery.
Optibrium and Collaborative Drug Discovery (CDD), developers of software products and services for drug discovery and development, are collaborating to integrate the StarDrop and CDD Vault platforms. This creates a seamless connection in real time between project data, securely held and managed in CDD Vault, and StarDrop’s unique compound design and optimisation capabilities. Instant access to the latest assay and compound data, with which a project team can share, interpret and model their chemistry, will lead to better decisions and shorter project timelines.
CDD Vault is a hosted biological and chemical database that securely manages project data. It allows researchers, across academic laboratories, research foundations, as well as small and large companies, to intuitively organise chemical structures and biological study data. CDD Vault supports a unique collaborative model that enables data to be safely shared with internal or external partners through an easy-to-use web interface.
Researchers can now seamlessly retrieve their biological results from CDD Vault using an intuitive search interface within StarDrop that enables users to easily run CDD Vault queries, returning the results directly in StarDrop. This extension to StarDrop is available free of charge to existing StarDrop and CDD Vault users, providing a highly visual way to interpret these data and their relationships with compound structures, clearly highlighting the best chemistries and multi-parameter optimisation strategies for drug discovery.
Dr Matthew Segall, CEO of Optibrium, commented: “When selecting compounds the importance of working with the most up-to-date data can’t be over stated – incomplete or out-of-date information results in time and effort being wasted. With this in mind, our aim is for StarDrop to fully integrate with the very ‘best in class’ drug discovery informatics platforms and we are delighted to be working with CDD to support drug discovery project teams to make good decisions and achieve their optimisation goals faster.”
Dr Barry Bunin, CEO CDD, added: “CDD understands that efficiency in modern drug discovery is a function of how well the industry's thought leaders work together. To that end, we are delighted to collaborate with Optibrium through this integration between StarDrop and CDD Vault. CDD Vault is particularly strong for project teams working across disciplines and, when coupled with StarDrop's unique ability to help scientists make confident and objective decisions, will undoubtedly help drug discovery project teams manage, analyze, and present chemical structures and biological assay data."
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance